Objective: To review current knowledge regarding the prevalence of somatization problems in later life by level of caseness (somatoform disorders and medically unexplained symptoms, MUS) and to compare these rates with those in middle-aged and younger age groups. Method: A systematic search of the literature published from 1966 onwards was conducted in the Pubmed and EMBASE databases. Results: Overall 8 articles, describing a total of 7 cohorts, provided data of at least one prevalence rate for somatoform disorders or MUS for the middle-aged (50-65 years) or older age (≥65 years) group. Prevalence rates for somatoform disorders in the general population range from 11 to 21% in younger, 10 to 20% in the middle-aged, and 1.5 to 13% in the older age groups. Prevalence rates for MUS show wider ranges, of respectively 1.6-70%, 2.4-87%, and 4.6-18%, in the younger, middle, and older age groups, which could be explained by the use of different instruments as well as lack of consensus in defining MUS. Conclusion: Somatoform disorders and MUS are common in later life, although the available data suggest that prevalence rates decline after the age of 65 years. More systematic research with special focus on the older population is needed to understand this age-related decline in prevalence rates.
Introduction
Medically unexplained symptoms (MUS) are physical symptoms of which presence, severity or consequences cannot be conclusively explained by any detectable physical disorder (Lipowski, 1988) . MUS are common in the general population with reported prevalence rates in primary care varying between 25 and 50% (Burton, 2003; Escobar et al., 2010; olde Hartman et al., 2009) . Within the International Classification of Diseases version 10 (ICD-10) as well as the Diagnostic and Statistical Manual for Mental Disorders version IV (DSM-IV), medically unexplained symptoms are classified under the section of somatoform disorders. In order to meet the official criteria for any of these somatoform disorders, the ICD-10 places emphasis on 'a psychological cause' of bodily symptoms, whereas in the DSM-IV for most somatoform disorders a psychological cause has to be assumed and most emphasis is placed on the presence of significant impairment in social, occupational and/or other areas of functioning due to MUS. Reported prevalence rates for all forms of somatoform disorders together vary from 10 to 25% in primary care (de Waal et al., 2004; Dekker et al., 2008; Faravelli et al., 1997; Roca et al., 2009; Steinbrecher et al., 2011) . Whether somatization, the tendency to express psychological distress with somatic complaints, is more common in old age remains a matter of debate (Creed and Barsky, 2004; Schneider and Heuft, 2011; Sheehan and Banerjee, 1999) .
Patients with MUS or somatoform disorder report significant decreases in quality of life, impairment in daily functioning, increased high health care utilization, and often undergo medical examinations and treatments unnecessarily (Barsky et al., 2005; Koch et al., 2007; Margalit and El-Ad, 2008) . In an adult population, MUS double the costs for both inpatient and outpatient health care utilization compared to patients without MUS when adjusted for the presence of comorbid psychiatric and somatic disease (Barsky et al., 2005) . Moreover, the increase of health care utilization over a follow-up period of 5 years was higher in MUS patients than in patients without MUS (Barsky et al., 2005) . Furthermore, this increase was higher than the increase associated with depressive disorder or anxiety disorders, disorders that are also associated with increased health care consumption over time (Grabe et al., 2009) . Increased medical consumption is not only problematic from an economical viewpoint, but also increases the risk of iatrogenic
